Telling Stories—and Editing—at Scale
Larry Birnbaum
Northwestern University
Dept. of EECS & Medill School of Journalism
Knight Lab
Narrative Science Inc.
February 9, 2012, Hockey Recap:
Rio Grande Valley rolls over Laredo, 6-3
The Rio Grande Valley Killer Bees were firing on all cylinders against the Laredo Bucks, and when the final
buzzer sounded Killer Bees emerged with a 6-3 win.
Zac Pearson was all over the ice for Rio Grande Valley, as he tallied two goals and one assist in the win.
Pearson scored the first of his two goals at 5:23 into the first period to make the score 1-0 Rio Grande Valley.
Brandon Campos picked up the assist. Pearson's next tally made the score 2-0 Rio Grande Valley with 12:44
left in the first period. David Marshall assisted on the tally.
The Rio Grande
Valley
Killer
Bees
were
The punch line...
firing on all cylinders against the Laredo
and
when
the
final
sounded
The Bucks,
Killer Bees' goal total
was higher
than their
season
average. buzzer
Rio Grande Valley
averages two goals per
game. The Killer Bees could not stay out of the penalty box, as the team accrued 17 minutes in penalties
during
the game. Bees
The leading offender
was Jason Beeman,
whoa
totaled
five minutes
in penalty time with one
Killer
emerged
with
6-3
win.
major. With 48 shots on target during the contest, Rio Grande Valley exceeded the 22 shots it averages per
Special teams units factored heavily in the game's outcome, as there were 14 penalties called on the two
teams. The busiest period in the sin bins was the first period, which saw 18 minutes of penalty time combined
between the two teams.
game this year.
Rio Grande Valley additionally got points from Aaron Lee, who had one goal and one assist, Marshall, who
registered one goal and two assists, and Dan Gendur, who racked up one goal and one assist. Dan Nicholls
also scored for Rio Grande Valley. Others to record assists for Rio Grande Valley were AJ Mikkelsen, who had
two and Adam Bartholomay and Marc-Andre Carre, who each chipped in one.
Laredo was often in penalty trouble, as it ended with six minors and one major for 17 minutes in penalty time.
The leading offender was Justin Styffe, who totaled nine minutes in penalty time with two minors and one
More than Sports: Business…
Medicine…
INVESTIGATOR
SITE
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
53398 5.88E+09
PATIENT
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
10031002
This 48-year-old White female subject in Canada with a medical
history of diarrhea, ovarian cyst, asthma, depression,
hypertension, GI upset, cholecystectomy and hysterectomy
received CP-690,550 for the treatment of active rheumatoid
arthritis. The subject was treated with CP-690,550 orally, 5 mg
twice daily, at a total daily dose of 10 mg, from 07 Apr 2010
(Study Day 1) to 09 Sep 2010, for a total of 156 days.
EVENT
SUBEVENT DCM DATE DCM TIME
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
SCREENING
1
DCI NAME DCM NAMESUBSET NAME
QUESTION GROUP
QUESTION
NAME
NAME
O_SN
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_TIME
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_DATE
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_ND
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_TPD
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_TPP
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_SAMP_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A003_V3
LAB_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
LAB_LOAD_V3_1
LAB_LOAD_V3_1
LBL_1
LAB_A004_V3
LAB_TEST_ID
R_SN
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
DATA VALUEDATA COMMENT
QUALIFYINGSTUDYT
VALUE
105800
CENTRAL LAB
A3921032
1
20100223
CENTRAL LAB
A3921032
1
CENTRAL LAB
A3921032
1
CENTRAL LAB
A3921032
1
CENTRAL LAB
A3921032
1
H099322
CENTRAL LAB
A3921032
1
140
CENTRAL LAB
A3921032
1
CNT69
CENTRAL LAB
A3921032
1
CNT63
CENTRAL LAB
A3921032
1
RCT30
CENTRAL LAB
A3921032
1
RCT1
CENTRAL LAB
A3921032
1
RCT11
CENTRAL LAB
A3921032
1
RCT13
CENTRAL LAB
A3921032
1
RCT14
CENTRAL LAB
A3921032
1
RCT1407
CENTRAL LAB
A3921032
1
RCT15
CENTRAL LAB
A3921032
1
RCT16
CENTRAL LAB
A3921032
1
RCT17
CENTRAL LAB
A3921032
1
RCT18
CENTRAL LAB
A3921032
1
RCT183
CENTRAL LAB
A3921032
1
RCT29
CENTRAL LAB
A3921032
1
RCT3
CENTRAL LAB
A3921032
1
RCT392
CENTRAL LAB
A3921032
1
RCT4
CENTRAL LAB
A3921032
1
RCT5
CENTRAL LAB
A3921032
1
RCT6
CENTRAL LAB
A3921032
1
SCT1528
CENTRAL LAB
A3921032
1
AXT542
CENTRAL LAB
A3921032
1
HMT10
CENTRAL LAB
A3921032
1
HMT11
CENTRAL LAB
A3921032
1
HMT12
CENTRAL LAB
A3921032
1
HMT13
CENTRAL LAB
A3921032
1
HMT15
CENTRAL LAB
A3921032
1
HMT16
CENTRAL LAB
A3921032
1
HMT17
CENTRAL LAB
A3921032
1
HMT18
CENTRAL LAB
A3921032
1
HMT19
CENTRAL LAB
A3921032
1
HMT2
CENTRAL LAB
A3921032
1
HMT3
CENTRAL LAB
A3921032
1
HMT40
CENTRAL LAB
A3921032
1
HMT7
CENTRAL LAB
A3921032
1
HMT8
CENTRAL LAB
A3921032
1
HMT9
CENTRAL LAB
A3921032
1
UAT2
CENTRAL LAB
A3921032
1
UAT3
CENTRAL LAB
A3921032
1
Civic Data…
…and Unstructured Data Too
NEWT GINGRICH GAINS ATTENTION WITH HOT-BUTTON TOPICS TAXES, CHARACTER
ISSUES
Newt Gingrich received the largest increase in Tweets about him today. Twitter activity associated
with the candidate has shot up since yesterday, with most users tweeting about taxes and
character issues. Newt Gingrich has been consistently popular on Twitter, as he has been the top
riser on the site for the last four days. Conversely, the number of tweets about Ron Paul has
dropped in the past 24 hours. Another traffic loser was Rick Santorum, who has also seen tweets
about him fall off a bit.
While the overall tone of the Gingrich tweets is positive, public opinion regarding the candidate
and character issues is trending negatively. In particular, @MommaVickers says, "Someone
needs to put The Blood Arm's 'Suspicious Character' to a photo montage of Newt Gingrich.
#pimp”.
On the other hand, tweeters with a long reach are on the upside with regard to Newt Gingrich's
take on taxes. Tweeting about this issue, @elvisroy000 says, "Newt Gingrich Cut Taxes Balanced
Budget, 1n 80s and 90s, Newt experienced Conservative with values”.
Maine recently held its primary, but it isn't talking about Gingrich. Instead the focus is on Ron Paul
and religious issues.
Why Stories?
Q1 - 2010
Gross
Profit
Sales
Q2 - 2010 Q3 - 2010
Q4 - 2010
Q1 - 2011
Q2 - 2011
Q3 - 2011
Q4 - 2011
Q1 - 2012
Q2 - 2012
Over the past eight quarters, AmgenCorp has seen a
steady increase in both sales and gross profit. During
this
period, however, two trends have become
$60,000,000
apparent.
Q3 - 2012
$9,600,000 $12,402,000
$15,774,720
$19,750,349
$24,334,442
$29,497,712
$35,168,885
$41,229,808
$47,513,986
$53,809,589 $59,867,622
$12,000,000 $15,600,000
$19,968,000
$25,159,680
$31,198,003
$38,061,564
$45,673,877
$53,895,174
$62,518,402
$71,270,979 $79,823,496
$50,000,000
While
sales have increased, there has been a steady
$40,000,000
decrease in margins which should be cause for concern.
Gross Profit
$30,000,000
Sales
In$20,000,000
addition, while we have seen quarter-to-quarter
increases in both sales and gross profit, each of these
$10,000,000
metrics
is decelerating, indicating that the business is
experiencing
a slow down.
$Q1 - 2010
Q2 - 2010
Q3 - 2010
Q4 - 2010
Q1 - 2011
Q2 - 2011
Q3 - 2011
Q4 - 2011
Narrative Analytics
• Stories embody high-level patterns or themes
that are efficiently communicated and
effectively grasped—e.g., comeback, fade, lowhanging fruit, etc.
• Stories pick out, connect, and summarize the
critical aspects of a situation
• Stories explain: They convey trends, causes,
and even recommendations
• Stories make data meaningful.
First Prototype Developed at Northwestern
The Story
Big Data Made Personal
CAPITAL MARKETS RESEARCH
SPRINT NEXTEL
March 2, 2012
Inside the Fundamentals - Financing and Interest & Debt Coverage
Factor
DATE
Trend VS
Peers
Debt/EBITDA
Debt/Net
Worth
EBIT/Interest
TICKER
Expense
CFO- S
Dividends/CA
PEX S
Debt Service
S
N/A
Last 12
Months (LTM)
TICKER
2010
Change
12/31/2011
5.14x
4.51x
N/A
N/A
N/A
9/30/2011
S
0.6%
N/A
S
SHORT
TERM
DEBT
Industry
Industry
Industry Change
Average
(LTM)
1.54x
N/A
Average 2010
2.15x
N/A
-28.5%
N/A
LONG TERM DEBT
8
2257
CURRENT ACCOUNTS TOTAL
COST OF
5.16x
3.37x
0%
ASSETS
CASH
SALES
6/30/2011ASSETS -46.7%
SPAYABLE
2256
N/A
1.18
2.49
-52.6%
2.8%
1.5%
12/31/11
0:00
10337
1887
49383 82.1%
5597
5419
3/31/2011
9/30/11 0:00
8650S
2188
48015
400122564611
N/A
N/A
N/A
N/A
N/A
N/A
6/30/11
0:00
9182
3035
49043 N/A
4271
4589
12/31/2010
S
3/31/11
0:00
8447
2738
49320 N/A
399816564396
Asset S
N/A
N/A
N/A
N/A
N/A
N/A
Coverage
S
12/31/10
0:00
9880
2131
51654 -79.8%
5473
FCF/Interest
N/A
0.39x
1.95x
-79.8%
4.07x
1.73x
9/30/2010
S
17584568
Expense
S
9/30/10 0:00
9255
2423
52274
4666
4496
! company's
S
6/30/10
0:00 of
8955
2494
53226
427717584230
The
financial leverage
(Debt/EBITDA)
6/30/2010
!! S
5.14x isSabove the industry median
of 2.16x
and up from 8835
3/31/10
0:00
2282
54282
4374
4198
4.51x a year ago as seen in 3/31/2010
figure 4. The increase looks
S
12/31/09
0:00
8593S
1575
55424
392424154079
to be driven by a decline in EBITDA, which fell 11.8%
S ago. A leverage ratio
9/30/09
2161
55648
5943
4269
from a year
this high0:00
in absolute 10259
12/31/2009
terms and
could impact
the
S should it continue,
6/30/09
0:00
9098S
2061
55885
4609 7684061
company's performance in the future.
S
3/31/09 0:00
8903
2105
57225
4536
9/30/2009
S
7654026
As seenSin figure 5, the company's
coverage
12/31/08
0:00
8344
1574
58252
3719
4122
(EBIT/Interest Expense), though negative, moved nearer
S
9/30/08
0:00
9266S
2582
61861
419113734224
to zero to -0.64x from -1.2x a6/30/2009
year ago. The industry's
6/30/08
8941
2481
62805
3501
4177
medianScoverage ratio was 3.51x.
Going 0:00
from -$1.77
billion aSyear ago to -$911 million,
a change
in EBIT
3/31/2009
3/31/08
0:00
10327S
3264
65463
477512254223
primarily drove the change. In absolute terms, a
S
12/31/07
0:00
8661
2750
64109
2440
4237
negative coverage ratio means
that the company is not
12/31/2008
0:00payments 8920S
3320
93926
2243 6184222
creatingSthe earnings needed9/30/07
to cover interest
on debt.SShould this continue,6/30/07
it could weigh
on
0:00
9278
3309
94895
2424
9/30/2008
S
16174342
company performance.
S
3/31/07 0:00
8947
3307
95089
2354
4390
As seenSin figure 6, Capex/Sales
rose from
5.94x a year10304
12/31/06
0:00
2366
97161
2061 6264320
6/30/2008
S
ago to 9.29x for the quarter ended Dec. 31, 2011 driven
T rise in Capex. With
12/31/11
0:00
23027
8593
270344
3185
11194
by a 61.8%
Capex/Depreciation
T and Capex growth3/31/2008
9/30/11
28605S
17860
277653 107621330
13165
below one
outstripping0:00
the rise in
sales, there
impact on operating
T could be a future6/30/11
0:00
22239
18145
272014
3831
13332
margins because the company
will have trouble
12/31/2007
S
1661
T
3/31/11 0:00
19737
18349
268085
1391
13403
covering the capital expenditures. While the company
12/31/10
0:00
7437
268488
1437 429
13939
appearsTto be investing in fixed
assets, the
company's 19951
9/30/2007
S
total debt
billion0:00
to signal the 21977
T remained level at $20.27
9/30/10
18417
269252
3246
13605
company isn't taking on significantly more debt, but free
T
6/30/10
0:00
21392
18157
267556
1377
12452
6/30/2007
S
1185
cash flow fell 80.5% from a year earlier, signaling the
T may not be generating
3/31/10
18087
265701
2617
12383
company
sufficient0:00
cash flow to 22362
3/31/2007
cover future
T capital expenditures.
12/31/09
0:00
24334S
7514
268752
3802 419
12974
T
9/30/09 0:00
25921
18093
266568
6167
12839
12/31/2006
S
1143
T
6/30/09 0:00
26940
18046
267918
7348
12557
T
3/31/09 0:00
23521
17359
264358
3812
12201
T
12/31/08 0:00
22556
6921
265245
1792
12642
T
9/30/08 0:00
23445
18690
284528
1594
13022
T
6/30/08 0:00
23225
18927
284508
1631
11897
2
MARCH 2, 2012
DATE
N/A
-0.64x
-1.2x
DEBT IN
CURRENT
LIABILITIES
DEPRECIATION
EXPENSE
SALES
CAPEX
20266
1174
8722
909
16272
1194
8333
818
DEBT IN LONG
DEPRECIATION AND
TERM
LIABILITIES AMORTIZATION 1235NET INCOME INVENTORIES
16278
8311
8
20266
1174
-1303
913
16282 16272
1255
2257
1194
-301 8313
923
2256
16278
1235
-847
1160
18535 16282
1386
2256
1255
-439 8301
728
1656
18535
1386
-929
670
18540
1552
8152
1758
18540
1552
-911
562
1758
1635
-760 8025
675
18543 18543
1635
2415
18639
1675
-865
526
18639 20293
1675
768
1802
-980 8085
628
765
20892
1820
-478
485
20293 19618
1802
1373
1911
-384 7868
575
1225
1870
-594
20892 20376
1820
8042 510
618
20992
1992
-1621
528
1617
2057
-326 8141
682
19618 21023
1911
626
22358
2157
-344
625
20376 22987
1870
1330
2190
-505 8209
842
1661
20469
2220
-29452
938
20992 21723
1992
429
2222
64 8430
876
1185
2313
19
21023 21713
2057
8816 1018
419
21752
2268
-211
884
1143
2404
261 9055 1176
22358 21011
2157
3453
61300
4573
-6678
1188
22987 62326
2190
8900
4618
3623 93341216.75
7910
58663
4602
3591
1245.5
20469 58126
2220
98471274.25
6902
4584
3408
7196
4907
1087 10044 1303
21723 58971
2222
6426
62540
4873
11539
1198.5
9721
4819
4008 10163 1094
21713 60277
2313
9437
60024
4780
2451
989.5
21752 64720
2268
7361
4966
2716 10092
885
6755
65909
4816
3077
879.25
21011 66565
2404
10438 873.5
10155
4875
3195
10790
63560
4858
3130
867.75
14119
60872
5044
2404
862
17419
59355
4978
3230
926.25
16472
63675
4958
3772
990.5
While the company appears to be investing
in fixed assets, the company's total debt
remained level at $20.27 billion to signal
the company isn't taking on significantly
more debt, but free cash flow fell 80.5%
from a year earlier, signaling the company
may not be generating sufficient cash flow
to cover future capital expenditures.
759
644
523
490
417
505
484
402
340
377
610
703
899
1670
1671
1261
1577
1813
2411
Investment Research
While the company appears to be
investing in fixed assets, the company's
total debt remained level at $20.27 billion
to signal the company isn't taking on
significantly more debt, but free cash
flow fell 80.5% from a year earlier,
signaling the company may not be
generating sufficient cash flow to cover
future capital expenditures.
Sector Reporting
MRK (Merck & Co Inc.) erased early losses and rose 0.6% to
$31.26. The company recently announced its chairman is stepping
down.October
MRK6,stock
traded
in the rangeMIDDAY
of $31.21
- $31.56. MRK's
Thursday,
2011 12:00
PM: HEALTHCARE
COMMENTARY:
volume was 86.1% lower than usual with 2.5 million shares trading
The Healthcare (XLV) sector underperformed the market in early trading on Thursday. Healthcare
hands.
gains
11.1%
lower
thanandits
stocks
trailed Today's
the market by
0.4%. still
So far,leave
the Dowthe
rose stock
0.2%, theabout
NASDAQ
saw growth
of 0.8%,
theprice
S&P500three
was upmonths
0.4%.
ago.
Here are a few Healthcare stocks that bucked the sector's downward trend.
The Healthcare (XLV) sector underperformed the market
MRK (Merck & Co Inc.) erased early losses and rose 0.6% to $31.26. The company recently
in early
trading
ondown.
Thursday.
Healthcare
trailed
announced
its chairman
is stepping
MRK stock traded
in the range ofstocks
$31.21 - $31.56.
MRK's
volume was 86.1% lower than usual with 2.5 million shares trading hands. Today's gains still leave
the market by 0.4%. So far, the Dow rose 0.2%, the
the stock about 11.1% lower than its price three months ago.
NASDAQ saw growth of 0.8%, and the S&P500 was up
LUX (Luxottica Group) struggled in early trading but showed resilience later in the day. Shares rose
0.4%.
3.8%
to $26.92. LUX traded in the range of $26.48 - $26.99. Luxottica Group’s early share volume
was 34,155. Today's gains still leave the stock 21.8% below its 52-week high of $34.43. The stock
remains about 16.3% lower than its price three months ago.
Shares of UHS (Universal Health Services Inc.) are trading at $32.89, up 81 cents (2.5%) from the
previous close of $32.08. UHS traded in the range of $32.06 - $33.01…
Business Reporting
REST_KEY
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
1364
Rest Coop
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
SEA/TCA WA CP-0024
Reporting Day
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/2/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/3/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/4/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
1/5/10
Daypart Name
After 4PM
Afternoon
Breakfast
Dinner
Evening
Late Night
Lunch
Morning
Regular Menu
Total Day
After 4PM
Afternoon
Breakfast
Dinner
Evening
Late Night
Lunch
Morning
Regular Menu
Total Day
After 4PM
Afternoon
Breakfast
Dinner
Evening
Late Night
Lunch
Morning
Regular Menu
Total Day
After 4PM
Afternoon
Breakfast
Dinner
Evening
Late Night
Lunch
Morning
Regular Menu
Total Day
Daypart Description
4PM - Close
2PM - 4PM
Open - 10:30AM (11AM weekend)
4PM - 9PM
9PM - Close
11PM - 5AM
11AM - 2PM
Open - 11AM
10:30AM (11AM weekend) - Close
All hours
4PM - Close
2PM - 4PM
Open - 10:30AM (11AM weekend)
4PM - 9PM
9PM - Close
11PM - 5AM
11AM - 2PM
Open - 11AM
10:30AM (11AM weekend) - Close
All hours
4PM - Close
2PM - 4PM
Open - 10:30AM (11AM weekend)
4PM - 9PM
9PM - Close
11PM - 5AM
11AM - 2PM
Open - 11AM
10:30AM (11AM weekend) - Close
All hours
4PM - Close
2PM - 4PM
Open - 10:30AM (11AM weekend)
4PM - 9PM
9PM - Close
11PM - 5AM
11AM - 2PM
Open - 11AM
10:30AM (11AM weekend) - Close
All hours
Daypart Sales $ Daypart Transaction Qty
1529.84
235
539.2
75
1027.4
180
957.24
156
572.6
79
222.55
31
950.53
159
1027.4
180
3019.57
469
4046.97
649
1397.96
198
613.56
83
971.19
169
1138.37
157
259.59
41
48.15
9
909.53
133
971.19
169
2921.05
414
3892.24
583
1583.05
244
497.62
90
817.03
211
1248.88
187
334.17
57
65.43
10
869.66
162
858.89
222
2992.19
507
3809.22
718
1674.46
254
480.8
103
923.24
214
1313.03
200
361.43
54
38.15
8
927.75
163
996.56
227
3156.33
533
4079.57
747
Education
Quill Engage for Google Analytics
https://quillengage.narrativescience.com
18
Quill Engage – Weekly Report
19
More and More, Machines are Making
Editorial Judgments
What Values Underlie Their Decisions?
Editorial Algorithms Should Be Written in
Human Terms
 The factors and trade-offs they take into
account should be formulated in terms of
editorial values that make sense to people
 Their decision-making should be visible
and controllable by the people who build
them, deploy them, and use their results
 Journalists and technologists will need to
work together to make this happen
I Want to Give Editors / Users an Interface
Like This!
Thanks
 Colleagues (many), especially Kris Hammond,
Rich Gordon, Jeremy Gilbert, Zach Wise, and
Owen Youngman
 Students (scores), especially Nick Allen, John
Templon, Patrick McNally, Shawn O’Banion,
Miriam Boon, and Jason Cohn
 Funders, especially the John S. and James L.
Knight Foundation, the National Science
Foundation, and Google
 Narrative Science (for making it real)